Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (Graft Versus Host, GVH) Did Not Respond to Imatinib Mesylate.

NCT02891395 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT02891395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02891395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (Graft Versus Host, GVH) Did Not Respond to Imatinib Mesylate.
Lead sponsor
University Hospital, Lille
Phase
Phase 2
Overall status
Completed
Start date
December 24, 2012
Completion date
July 26, 2017
Enrollment
65 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease